Загрузка...
Emerging treatment options for the management of Hodgkin’s lymphoma: clinical utility of nivolumab
Classical Hodgkin’s lymphoma (cHL) is a B-cell malignancy comprised of pathologic Reed Sternberg cells with a surrounding immune-tolerant inflammatory milieu. RS cells evade immune recognition in part through programmed death ligand 1 (PD-L1) overexpression, which is genetically programmed through c...
Сохранить в:
| Опубликовано в: : | J Blood Med |
|---|---|
| Главные авторы: | , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
Dove Medical Press
2017
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5436782/ https://ncbi.nlm.nih.gov/pubmed/28546779 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/JBM.S117452 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|